Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ARMOUR Residential REIT, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while ARMOUR Residential REIT, Inc. trades at $16.92 (market cap $2.11B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 16.96% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ARR | |
|---|---|---|
Market Cap | $4.49B | $2.11B |
Sector | Health | Financials |
52-Week High | $28.06 | $19.12 |
52-Week Low | $20.06 | $14.05 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 16.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ARR trades at $16.98, down 0.88% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows a low P/E of 6.9 and P/B of 0.91, with strong net income margin of 95.99% in 2025. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 missed. Dividend payments of $0.24 per share continue consistently, supporting income appeal amid mixed analyst sentiment.
Outlook is cautious with 60% hold ratings; consensus target is $18.50 offering ~9% upside. Risks include volatile cash flows from large investing activities and reliance on dividend sustainability. Institutional sentiment is divided, with Zacks rating it Strong Sell on June 23, 2026, contrasting with some bullish dividend coverage analyses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →
